Childhood Immune Thrombocytopenic Purpura: Diagnosis and Management

Hematology/Oncology Clinics of North America

Volumn 24, Issue 1, 2010, Pages 249-273

  Blanchette, Victor ^a   Bolton Maggs, Paula ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Combined cytopenias; Immune thrombocytopenic purpura; Immunoglobulin G; Intravenous anti D; Splenectomy

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DAPSONE; DEXAMETHASONE; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PENICILLIN G; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISOLONE; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE ANTIBODY; THROMBOCYTE ANTIGEN; THROMBOPOIETIN; UNINDEXED DRUG; VINCA ALKALOID;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; AGE DISTRIBUTION; ANTIBIOTIC PROPHYLAXIS; ANTIBODY PRODUCTION; ASEPTIC MENINGITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; BEHAVIOR DISORDER; BLEEDING; BLOOD SMEAR; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CAPILLARY RESISTANCE; CELL DESTRUCTION; CHILD; CHILDHOOD DISEASE; CHILL; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; EMERGENCY CARE; EPISTAXIS; FAMILY HISTORY; FATIGUE; FEVER; GLUCOSURIA; HEADACHE; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HOSPITALIZATION; HUMAN; HYPERACTIVITY; HYPERGLYCEMIA; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOASSAY; IMMUNOLOGICAL TOLERANCE; INFECTION; INTRAVASCULAR HEMOLYSIS; LABORATORY DIAGNOSIS; LYMPHOPROLIFERATIVE DISEASE; MORNING DOSAGE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PALLOR; PATHOPHYSIOLOGY; PETECHIA; PHYSICAL EXAMINATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SPLENECTOMY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINE COLOR; VIRUS INFECTION; VOMITING;

CHILD; DISEASE MANAGEMENT; DISEASE SUSCEPTIBILITY; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 74749101374     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.11.004     Document Type: Review

References (112)

1. Cines D.B., and Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 346 (2002) 995-1008
2. Harrington W.J., Minnich V., Hollingsworth J.W., et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 38 (1951) 1-10
3. Shulman N.R., Marder V.J., and Weinrach R.S. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci 124 (1965) 499-542
4. Berchtold P., Muller D., Beardsley D., et al. International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol 96 (1997) 477-483
5. George J.N., Woolf S.H., Raskob G.E., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88 (1996) 3-40
6. Louwes H., Lathori O.A.Z., Vellenga E., et al. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med 106 (1999) 430-434
7. Takahashi R., Sekine N., and Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood 93 (1999) 1951-1958
8. Cremer M., Schulze H., Linthorst G., et al. Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias. Ann Hematol 78 (1999) 401-407
9. Payne B.A., and Pierre R.V. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 59 (1984) 123-125
10. Lowe E.J., and Buchanan G.R. Idiopathic thrombocytopenic purpura diagnosed during the second decade of life. J Pediatr 141 (2002) 253-258
11. Drachman J.G. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 103 (2004) 390-398
12. Kühne T., Imbach P., Bolton-Maggs P.H.B., et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 358 (2001) 2122-2125
13. Kühne T., Buchanan G.R., Zimmerman S., et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 143 (2003) 605-608
14. Bolton-Maggs P.H.B., and Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenia purpura against published guidelines. Lancet 350 (1997) 620-623
15. Sutor A.H., Harms A., and Kaufmehl K. Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany. Semin Thromb Hemost 27 (2001) 253-267
16. Rosthoj S., Hedlund-Treutiger I., Rajantie J., et al. Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children. A prospective Nordic study of an unselected cohort. J Pediatr 143 (2003) 302-307
17. Oski F.A., and Naiman J.L. Effect of live measles vaccine on the platelet count. N Engl J Med 275 (1966) 352-356
18. Miller E., Waight P., Farrington C.P., et al. Idiopathic thrombocytopaenic purpura and MMR vaccine. Arch Dis Child 84 (2001) 227-229
19. Black C., Kaye J.A., and Jick H. MMR vaccine and idiopathic thrombocytopenic purpura. Br J Clin Pharmacol 55 (2003) 107-111
20. Choi S.I., and McClure P.D. Idiopathic thrombocytopenic purpura in childhood. Can Med Assoc J 97 (1967) 562-568
21. Lusher J.M., and Zuelzer W.W. Idiopathic thrombocytopenic purpura in childhood. J Pediatr 68 (1966) 971-979
22. Blanchette V.S., and Carcao M. Childhood acute immune thrombocytopenic purpura: 20 years later. Semin Thromb Hemost 29 (2003) 605-617
23. Edslev P.W., Rosthøj S., Treutiger I., et al. A clinical score predicting a brief and uneventful course of newly diagnosed idiopathic thrombocytopenic purpura in children. Br J Haematol 138 (2007) 513-516
24. Imbach P., Kühne T., Müller D., et al. Childhood ITP: 12 months follow-up data from the prospective Registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 46 (2006) 351-356
25. Reid M.M. Chronic idiopathic thrombocytopenic purpura: incidence, treatment and outcome. Arch Dis Child 72 (1995) 125-128
26. Imbach P., Akatsuka J., Blanchette V., et al. Immunthrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity. Eur J Pediatr 154 Suppl 3 (1995) S60-S64
27. Lilleyman J.S. On behalf of the Paediatric Haematology Forum of the British Society of Haematology. Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Arch Dis Child 71 (1994) 251-253
28. Lee M.S., and Kim W.C. Intracranial hemorrhage associated with idiopathic thrombocytopenic purpura: report of seven patients and a meta-analysis. Neurology 50 (1998) 1160-1163
29. Butros L.J., and Bussel J.B. Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol 25 (2003) 660-664
30. Woerner S.J., Abildgaard C.F., and French B.N. Intracranial hemorrhage in children with idiopathic thrombocytopenic purpura. Pediatrics 67 (1981) 453-460
31. Medeiros D., and Buchanan G.R. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr 133 (1998) 334-339
32. Bolton-Maggs P.H.B., Dickerhoff R., and Vora A.J. The non-treatment of childhood ITP (or "The art of medicine consists of amusing the patient until nature cures the disease"). Semin Thromb Hemost 27 (2001) 269-275
33. Eden O.B., and Lilleyman J.S. On behalf of the British Paediatric Haematology Group. Guidelines for management of idiopathic thrombocytopenic purpura. Arch Dis Child 67 (1992) 1056-1058
34. Lilleyman J.S. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol 105 (1999) 871-875
35. De Mattia D., Del Principe D., Del Vecchio G.C., et al. Acute childhood idiopathic thrombocytopenic purpura: AIEOP concensus guidelines for diagnosis and treatment. Haematologica 85 (2000) 420-424
36. Provan D., Newland A., Norfolk D., et al. Working Party of the British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 120 (2003) 574-596
37. Dickerhoff R., and von Ruecker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr 137 (2000) 629-632
38. Sartorius J.A. Steroid treatment of idiopathic thrombocytopenic purpura in children. Preliminary results of a randomized cooperative study. Am J Pediatr Hematol Oncol 6 (1984) 165-169
39. Buchanan G.R., and Holtkamp C.A. Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A randomized clinical trial. Am J Pediatr Hematol Oncol 6 (1984) 355-361
40. Özsoylu S., Sayli T.R., and Öztürk G. Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 10 (1993) 317-321
41. Suarez C.R., Rademaker D., Hasson A., et al. High-dose steroids in childhood acute idiopathic thrombocytopenia purpura. Am J Pediatr Hematol Oncol 8 (1986) 111-115
42. van Hoff J., and Ritchey A.K. Pulse methylprednisolone therapy for acute childhood idiopathic thrombocytopenic purpura. J Pediatr 113 (1988) 563-566
43. Jayabose S., Patel P., Inamdar S., et al. Use of intravenous methylprednisolone in acute idiopathic thrombocytopenic purpura. Am J Pediatr Hematol Oncol 9 (1987) 133-135
44. Carcao M.D., Zipursky A., Butchart S., et al. Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP). Acta Paediatr Suppl 424 (1998) 71-74
45. Beck C.E., Nathan P.C., Parkin P.C., et al. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr 147 (2005) 521-527
46. Imbach P., Barandun S., d'Apuzzo V., et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet (1981) 1228-1231
47. Blanchette V.S., Luke B., Andrew M., et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 123 (1993) 989-995
48. Blanchette V., Imbach P., Andrew M., et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 344 (1994) 703-707
49. Imbach P., Wagner H.P., Berchtold W., et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet (1985) 464-468
50. Salama A., Mueller-Eckhardt C., and Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells?. Lancet (1983) 193-195
51. Scaradavou A., Woo B., Woloski B.M.R., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 89 (1997) 2689-2700
52. Tarantino M.D., Young G., Bertolone S.J., et al. Single dose of anti-D immune globulin at 75 μg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 148 (2006) 489-494
53. Newman G.C., Novoa M.V., Fodero E.M., et al. A dose of 75 μg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 μg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 112 (2001) 1076-1078
54. o(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 106 (2005) 1532-1537
55. Calpin C., Dick P., Poon A., et al. Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukemia?. Arch Pediatr Adolesc Med 152 (1998) 345-347
56. Blanchette V.S., and Price V. Childhood chronic immune thrombocytopenic purpura: unresolved issues. J Pediatr Hematol Oncol 25 (2003) S28-S33
57. Mantadakis E., and Buchanan G.R. Elective splenectomy in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 22 (2000) 148-153
58. Ben-Yehuda D., Gillis S., Eldor A., et al. Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Acta Haematol 91 (1994) 1-6
59. Blanchette V.S., Kirby M.A., and Turner C. Role of intravenous immunoglobulin G in autoimmune hematologic disorders. Semin Hematol 29 (1992) 72-82
60. Aronis S., Platokouki H., Avgeri M., et al. Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatr 93 (2004) 638-642
61. Kühne T., Blanchette V., Buchanan G.R., et al. Splenectomy in children with idiopathic thrombocytopenic purpura: a prospective study of 134 children from the Intercontinental Childhood ITP Study Group. Pediatr Blood Cancer 49 (2007) 829-834
62. Wang T., Xu M., Ji L., et al. Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single centre study in China. Acta Haematol 115 (2006) 39-45
63. 111 In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J Haematol 97 (1997) 547-550
64. Holt D., Brown J., Terrill K., et al. Response to intravenous immunoglobulin predicts splenectomy response in children with immune thrombocytopenic purpura. Pediatrics 111 (2003) 87-90
65. Bussel J.B., Kaufmann C.P., Ware R.E., et al. Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy?. Am J Hematol 67 (2001) 27-33
66. Price V.E., Dutta S., Blanchette V.S., et al. The prevention and treatment of bacterial infections in children with asplenia or hyposplenia: practice considerations at the Hospital for Sick Children, Toronto. Pediatr Blood Cancer 46 (2006) 597-603
67. Baumann M.A., Menitove J.E., Aster R.H., et al. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med 104 (1986) 808-809
68. Barnes C., Blanchette V., Canning P., et al. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med 15 (2005) 145-150
69. Wang W.C. Evans syndrome in childhood: pathophysiology, clinical course, and treatment. Am J Pediatr Hematol Oncol 10 (1988) 330-338
70. Savaşan S., Warrier I., and Ravindranath Y. The spectrum of Evans' syndrome. Arch Dis Child 77 (1997) 245-248
71. Mathew P., Chen G., and Wang W. Evans syndrome: results of a national survey. J Pediatr Hematol Oncol 19 (1997) 433-437
72. Blouin P., Auvrignon A., Pagnier A., et al. [Evans' syndrome: a retrospective study from the ship (french society of pediatric hematology and immunology) (36 cases)]. Arch Pediatr 12 (2005) 1600-1607 [in French]
73. Calderwood S., Blanchette V., Doyle J., et al. Idiopathic thrombocytopenia and neutropenia in childhood. Am J Pediatr Hematol Oncol 16 (1994) 95-101
74. Norton A., and Roberts I. Management of Evans syndrome. Br J Haematol 132 (2005) 125-137
75. Scaradavou A., and Bussel J. Evans syndrome: results of a pilot study utilizing a multiagent treatment protocol. J Pediatr Hematol Oncol 17 (1995) 290-295
76. Uçar B., Akgün N., Aydoǧdu S.D., et al. Treatment of refractory Evans' syndrome with cyclosporine and prednisone. Pediatr Int 41 (1999) 104-107
77. Williams J.A., and Boxer L.A. Combination therapy for refractory idiopathic thrombocytopenic purpura in adolescents. J Pediatr Hematol Oncol 25 (2003) 232-235
78. Cunningham-Rundles C. Hematologic complications of primary immune deficiencies. Blood Rev 16 (2002) 61-64
79. Michel M., Chanet V., Galicier L., et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency. Analysis of 21 cases and review of the literature. Medicine 83 (2004) 254-263
80. Knight A.K., and Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev 5 (2006) 156-159
81. Brandt D., and Gershwin M.E. Common variable immune deficiency and autoimmunity. Autoimmun Rev 5 (2006) 465-470
82. Wang J., and Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 25 (2005) 57-62
83. Sneller M.C., Dale J.K., and Straus S.E. Autoimmune lymphoproliferative syndrome. Curr Opin Rheumatol 15 (2003) 417-421
84. Oliveira J.B., and Fleischer T. Autoimmune lymphoproliferative syndrome. Curr Opin Allergy Clin Immunol 4 (2004) 497-503
85. Rao V.K., and Straus S.E. Causes and consequences of the autoimmune lymphoproliferative syndrome. Hematology 11 (2006) 15-23
86. Worth A., Thrasher A.J., and Gaspar H.B. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol 133 (2006) 124-140
87. Savaşan S., Warrier I., Buck S., et al. Increased lymphocyte Fas expression and high incidence of common variable immunodeficiency disorder in childhood Evans' syndrome. Clin Immunol 125 (2007) 224-229
88. Teachey D.T., Manno C.S., Axsom K.M., et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 105 (2005) 2443-2448
89. Rao V.K., Dugan F., Dale J.K., et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 129 (2005) 534-538
90. Vesely S.K., Perdue J.J., Rizvi M.A., et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy. A systematic review. Ann Intern Med 140 (2004) 112-120
91. Arnold D.M., Dentali F., Crowther M.A., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146 (2007) 25-33
92. Bennett C.M., Rogers Z.R., Kinnamon D.D., et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107 (2006) 2639-2642
93. Cooper N., Stasi R., Cunningham-Rundles S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125 (2004) 232-239
94. Perrotta A.L. Re-treatment of chronic idiopathic thrombocytopenic purpura with Rituximab: literature review. Clin Appl Thromb Hemost 12 (2006) 97-100
95. Larrar S., Guitton C., Willems M., et al. Severe hematological side effects following Rituximab therapy in children. Haematologica 91 (2006) 101-102
96. Anonymous. Rituxan warning. FDA Consum 41 (2007) 2
97. Kaushansky K. Thrombopoietin. N Engl J Med 339 (1998) 746-754
98. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98 (2001) 3241-3248
99. Erickson-Miller C.L., DeLorme E., Tian S.S., et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 33 (2005) 85-93
100. Kuter D.J. New thrombopoietic growth factors. Blood 109 (2007) 4607-4616
101. Newland A., Caulier M.T., Kappers-Klunne M., et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 135 (2006) 547-553
102. Bussel J.B., Kuter D.J., George J.N., et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355 (2006) 1672-1681
103. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357 (2007) 2237-2247
104. Bolton-Maggs P.H.B. Management of immune thrombocytopenic purpura. Paediatr Child Health 17 (2007) 305-310
105. Buchanan G.R., and Adix L. Outcome measures and treatment endpoints other than platelet count in childhood idiopathic thrombocytopenic purpura. Semin Thromb Hemost 27 (2001) 277-285
106. Barnard D., Woloski M., Feeny D., et al. Development of disease-specific health-related quality of life instruments for children with immune thrombocytopenic purpura and their parents. J Pediatr Hematol Oncol 25 (2003) 56-62
107. von Mackensen S., Nilsson C., Jankovic M., et al. Development of a disease-specific quality of life questionnaire for children and adolescents with idiopathic thrombocytopenic purpura (ITP-QoL). Pediatr Blood Cancer 47 (2006) 688-691
108. Klaassen R.J., Blanchette V.S., Barnard D., et al. Validity, reliability and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids' ITP Tools. J Pediatr 150 (2007) 510-515
109. Buchanan G.R., and Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 141 (2002) 683-688
110. Page K.L., Psaila B., Provan D., et al. The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol 138 (2007) 245-248
111. O'Brien S.H., Ritchey A.K., and Smith K.J. A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). Pediatr Blood Cancer 48 (2007) 173-180
112. Cines D.B., and Bussel J.B. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 106 (2005) 2244-2251